Browse studies
Find your next paid study
2 recruiting studies matching your filters
Feasibility Study of Individualized Treatment Recommendations for Acute Myeloid Leukemia Based on High Throughput Screening and Genomics Data
Every patient responds differently to their cancer treatment, and some treatments work better for some patients more than others. For patients with relapsed, r…
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Estimated
~$10 – $750
City of Hope Medical CenterNCT07613385
Phase 1
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelody…
Relapsed/Refractory Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
Estimated
~$10 – $8,750
Cullinan Therapeutics Inc.NCT05143996